Solifenacin treatment for overactive bladder in Hispanic patients: Patient-reported symptom bother and quality of life outcomes from the VESIcare® Open-Label Trial

International Journal of Clinical Practice

Volumn 62, Issue 1, 2008, Pages 39-46

  Capo' Jr , J P ^a   Laramee C ^b   Lucente, V ^c   Fakhoury, A ^d   Forero Schwanhaeuser, S ^e  

^a Internal Medicine Associates of Atlanta   (United States)

^b Clinical Research of West Florida Inc   (United States)

^c Institute for Female Pelvic Medicine   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOLIFENACIN;

ADULT; AGED; ARTICLE; BLURRED VISION; BRONCHITIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HEART PALPITATION; HISPANIC; HUMAN; HYPERTENSION; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOCTURIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RHINOPHARYNGITIS; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; VISUAL ANALOG SCALE; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATTITUDE TO HEALTH; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; QUINUCLIDINES; SEVERITY OF ILLNESS INDEX; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 37349103779     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01644.x     Document Type: Article

References (27)

1. Abrams P. Reviewing the ICS 2002 Terminology Report: the ongoing debate. Neurourol Urodyn 2006 25 : 293.
2. Coyne KS, Payne C, Bhattacharyya SK et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004 7 : 455 63.
3. Liberman JN, Hunt TL, Stewart WF et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001 57 : 1044 50.
4. Abrams P, Artibani W, Gajewski JB, Hussain I. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 2006 68 (2 Suppl. 17 28.
5. Khullar V, Chapple C, Gabriel Z, Dooley JA. The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology 2006 68 (2 Suppl. 38 48.
6. Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006 CD003193.
7. Lewis-Fernandez R, Das AK, Alfonso C et al. Depression in US Hispanics: diagnostic and management considerations in family practice. J Am Board Fam Pract 2005 18 : 282 96.
8. Ramirez AG, Villarreal R, Suarez L, Flores ET. The emerging Hispanic population: a foundation for cancer prevention and control. J Natl Cancer Inst Monogr 1995 18 : 1 9.
9. Bernstein R. Nation's Population One-third Minority. Washington, DC : U.S. Census Bureau News, U.S. Department of Commerce. http://www.census.gov/ Press-Release/www/releases/archives/population/006808.html (accessed March 2007).
10. U.S. Census Bureau. The Hispanic Population in the United States, 2004, Detailed Tables. http://www.census.gov/population/www/socdemo/hispanic/cps2004. html (accessed March 2007).
11. Bergman M. Census bureau projects tripling of Hispanic and Asian populations in 50 years; non-Hispanic Whites may drop to half of total population. Washington, DC : U.S. Census Bureau News, U.S. Department of Commerce. http://www.census.gov/Press-Release/www/releases/archives/population/ 001720.html (accessed March 2007).
12. Duong TH, Korn AP. A comparison of urinary incontinence among African American, Asian, Hispanic, and white women. Am J Obstet Gynecol 2001 184 : 1083 6.
13. Sampselle CM, Harlow SD, Skurnick J et al. Urinary incontinence predictors and life impact in ethnically diverse perimenopausal women. Obstet Gynecol 2002 100 : 1230 8.
14. Espino DV, Palmer RF, Miles TP et al. Prevalence and severity of urinary incontinence in elderly Mexican-American women. J Am Geriatr Soc 2003 51 : 1580 6.
15. Mattox TF, Bhatia, NN. The prevalence of urinary incontinence or prolapse among white and Hispanic women. Am J Obstet Gynecol 1996 174 : 646 8.
16. Mallett V, Burks D, Garely A, Smith N. Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes. Curr Med Res Opin 2007 23 : 821 31.
17. Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther 2006 28 : 1935 46.
18. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006 49 : 1079 86.
19. Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001 166 : 140 5.
20. Dmochowski RR, Sand PK, Zinner NR et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003 62 : 237 42.
21. Leung HY, Yip SK, Cheon C et al. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. BJU Int 2002 90 : 375 80.
22. Stach-Lempinen B, Kujansuu E, Laippala P, Metsanoja R. Visual Analogue Scale, urinary incontinence severity score and 15 D-psychometric testing of three different health-related quality-of-life instruments for urinary incontinent women. Scand J Urol Nephrol 2001 35 : 476 83.
23. Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002 11 : 563 74.
24. Matza LS, Zyczynski TM, Bavendam T. A review of quality-of-life questionnaires for urinary incontinence and overactive bladder: which ones to use and why? Curr Urol Rep 2004 5 : 336 42.
25. Matza LS, Thompson CL, Krasnow J et al. Test-retest reliability of four questionnaires for patients with overactive bladder: the Overactive Bladder Questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), Urgency Questionnaire (UQ), and the Primary OAB Symptom Questionnaire (POSQ). Neurourol Urodyn 2005 24 : 215 25.
26. Coyne KS, Matza LS, Thompson CL et al. Determining the importance of change in the Overactive Bladder Questionnaire. J Urol 2006 176 : 627 32.
27. Heit M, Blackwell L, Kelly S. A model for explaining differences in incontinence care seeking (Medics project). ICS 2004, Paris, France. Abstract 420.